Eiger chalks up one win, one loss between a pair of PhII rare disease drugs, reshuffling priorities
Months after Eiger Biopharmaceuticals conceded ubenimex had no effect in pulmonary arterial hypertension, the drug has proven to be a flop again — this time in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
